Du är här


Moberg Pharma: Redeye: Moberg Pharma - Extraordinarily strong 2Q18!

Moberg Pharma delivered strongly in 2Q18, driven by an impressive
performance in its US OTC business. Following the 2Q18 earnings
report, we are substantially raising our forecast, leading to an
increase in our valuation.

Read more and download the research update:

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment
Banking. https://www.redeye.se/about/


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.